Journal Article

Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Geist, Marie A, Manera, Umberto, Shefner, Jeremy M, Querin, Giorgia, Sideri, Riccardo, Szacka, Katarzyna, Meyer, Thomas, Statland, Jeffrey, Sanchez-Tejerina, Daniel, Broere, Bianca, Hanna, Michael G, Heim, Andrew, Berube, Maxime, Phung, Liane, Grudniak, Mariusz, Morales, Raul Juntas, Jones, Sarah, Salmon, Kristiana, Lillig, Katie, Levine, Todd, Holmgren, Monica, Van Daele, Sien, Boczkowska, Marcelina, Solorzano, Guillermo, Neuwirth, Christoph, Adamo, Ashley, Delmotte, Koen, Janse van Mantgem, Mark R, Jablońska, Dorota, Granit, Volkan, Vachon, Chris, Sonja, Körner, de Fockert, Arianne, Czarnecki, Maciej, Camu, William, Ludolph, Albert C, Turcotte, Nicole, Hernandez, Jessica, Landabaso, Carmen, Elman, Lauren, Agessandro, Abrahao, Alma, Osmanovic, van den Berg, Leonard H, Andersen, Peter M, Foucher, Juliette, Zinman, Lorne, Dang, Hoang, Hansen, Thomas, Blaettler, Thomas, Jabari, Duaa, Turner, Martin R, Paredes, Maria Elena, Bilsker, Martin, Farmakidis, Constantine, Pasnoor, Mamatha, Łuczak, Alina Zuzanna, Kuzma-Kozakiewicz, Magdalena, Chio, Adriano, Coudoin, Sylvie, Saunders, Natalie, Pavlakis, Pantelis, Ana

2024

Overview

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral sclerosis, with multiple mechanisms of action, including clearance of protein aggregates, a pathological hallmark of sporadic and familial amyotrophic lateral sclerosis. We aimed to evaluate the safety and efficacy of arimoclomol in patients with amyotrophic lateral sclerosis. ORARIALS-01 was a multinational, randomised, double-blind, placebo-controlled, parallel-group trial done at 29 centres in 12 countries in Europe and North America. Patients were eligible if they were aged 18 years or older and met El Escorial criteria for clinically possible, probable, probable laboratory-supported, definite, or familial amyotrophic lateral sclerosis; had an ALS Functional Rating Scale-Revised score of 35 or more; and had slow vital capacity at 70% or more of the value predicted on the basis of the participant's age, height, and sex. Patients were randomly assigned (2:1) in blocks of 6, stratified by use of a stable dose of riluzole or no riluzole use, to receive oral arimoclomol citrate 1200 mg/day (400 mg three times per day) or placebo. The Randomisation sequence was computer generated centrally. Investigators, study personnel, and study participants were masked to treatment allocation. The primary outcome was the Combined Assessment of Function and Survival (CAFS) rank score over 76 weeks of treatment. The primary outcome and safety were analysed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03491462, and is completed. Between July 31, 2018, and July 17, 2019, 287 patients were screened, 245 of whom were enrolled in the trial and randomly assigned. The modified intention-to-treat population comprised 239 patients (160 in the arimoclomol group and 79 in the placebo group): 151 (63%) were male and 88 (37%) were female; mean age was 57·6 years (SD 10·9). CAFS score over 76 weeks did not differ between groups (mean 0·51 [SD 0·29] in the arimoclomol group vs 0·49 [0·28] in the placebo group; p=0·62). Cliff's delta comparing the two groups was 0·039 (95% CI –0·116 to 0·194). Proportions of participants who died were similar between the treatment groups: 29 (18%) of 160 patients in the arimoclomol group and 18 (23%) of 79 patients in the placebo group. Most deaths were due to disease progression. The most common adverse events were gastrointestinal. Adverse events were more often deemed treatment-related in the arimoclomol group (104 [65%]) than in the placebo group (41 [52%]) and more often led to treatment discontinuation in the arimoclomol group (26 [16%]) than in the placebo group (four [5%]). Arimoclomol did not improve efficacy outcomes compared with placebo. Although available biomarker data are insufficient to preclude future strategies that target the HSP response, safety data suggest that a higher dose of arimoclomol would not have been tolerated. Orphazyme.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adult / Adverse events / Aged / Amyotrophic lateral sclerosis / Amyotrophic Lateral Sclerosis - drug therapy / Animal models / Double-Blind Method / Drug dosages / FDA approval / Female / Heat shock proteins / Hsp70 protein / Humans / Hydroxylamines - adverse effects / Hydroxylamines - pharmacology / Hydroxylamines - therapeutic use / Male / Middle Aged / Mutation / Neurodegenerative diseases / Neurons / Neuroprotection / Neuroprotective Agents - adverse effects / Neuroprotective Agents - therapeutic use / Ostomy / Oxadiazoles - adverse effects / Oxadiazoles - therapeutic use / Pathology / Patients / Placebos / Safety / Spinal cord / Tracheotomy / Transgenic animals / Treatment Outcome / Ventilation